Table 2

Concept mapping study population

DemographicsUlcerative colitisCrohn’s diseaseP value
Participants, no (%)13 (50)13 (50)N/A
Age, years, median (IQR)43 (36–49)42 (39–51)0.78
Women (cisgender), no (%)9 (69)8 (62)1.00
Disease duration, years, median (IQR)11 (5–15)17 (12–20)0.05
Montreal classification, no (%)N/A
Ulcerative colitis
Disease location
 E1 ulcerative proctitis1 (8)
 E2 left-sided8 (61)
 E3 extensive4 (31)
Severity
 S0 remission4 (31)
 S1 mild4 (31)
 S2 moderate5 (38)
 S3 severe0
Crohn’s disease
Age at diagnosis
 A1 <16 years3 (23)
 A2 17–40 years7 (54)
 A3 >40 years3 (23)
Disease location
 L1 terminal ileum2 (15)
 L2 colon4 (31)
 L3 ileocolonic5 (38)
 L4 isolated upper disease1 (8)
 L2+L4 colon+upper disease1 (8)
Behaviour
 B1 non-stricturing, non-penetrating4 (31)
 B2 stricturing6 (46)
 B3 penetrating0
 p* penetrating perianal3 (23)
Treatment, no (%)0.84
 Only biologics8 (61)6 (46)
 Only thiopurines1 (8)1 (8)
 Biologics+thiopurines4 (31)6 (46)
Type of biologic, no (%)N/A
 Infliximab8 (61)8 (61)
 Adalimumab1 (8)3 (23)
 Vedolizumab1 (8)1 (8)
 Golimumab2 (15)0
Treatment duration biologics, months, median (IQR)24 (16–27)27 (6–39)0.64
Concomitant treatment, no (%)N/A
 None (thiopurines not included)2 (15)13 (100)
 5-Aminosalicylic acid (5-ASA)11 (84)0
Previous number of biologics, no, median (IQR)0 (0–1)1 (0–1)0.22
Other chronic diseases, no (%)5 (38)6 (46)0.68
Patient-reported disease activity, no (%)
 Remission3 (23)9 (69)0.06
 Mild2 (15)1 (8)
 Moderate7 (54)2 (15)
 Severe01 (8)
 Unknown1 (8)0
 Fatigue, median VAS (IQR)4 (2–5)5 (2–7)0.48
 Pain, median VAS (IQR)2 (0–3)2 (1–3)0.79
Work status, no (%)0.5
 Employed9 (69)9 (69)
 Part-time employed2 (15)2 (15)
 Unemployed1 (8)2 (15)
 Student1 (8)0
  • *Perianal disease modifier.

  • N/A, not applicable; VAS, visual analogue scale.